View Item 

Show simple item record

Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options

dc.contributor.authorCaram, Megan V.en_US
dc.contributor.authorSchuetze, Scott M.en_US
dc.date.accessioned2011-12-05T18:33:19Z
dc.date.available2013-02-01T20:26:17Zen_US
dc.date.issued2011-12en_US
dc.identifier.citationCaram, Megan V.; Schuetze, Scott M. (2011). "Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options." Journal of Surgical Oncology 104(8): 888-895. <http://hdl.handle.net/2027.42/88051>en_US
dc.identifier.issn0022-4790en_US
dc.identifier.issn1096-9098en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/88051
dc.description.abstractGastrointestinal stromal tumor (GIST), the most common sarcoma arising in the gastrointestinal tract, typically expresses the tyrosine‐kinase receptor, C‐KIT, and contains activating mutation in the c‐kit or platelet‐derived growth factor receptor ( pdgfr ) gene. Recently, development of small molecules that inhibit the kinase activity of mutant C‐KIT and PDGFR proteins has radically changed treatment and prognosis of patients diagnosed with advanced GIST as this molecularly “targeted” therapy has demonstrated remarkable high‐level of activity in this disease. J. Surg. Oncol. 2011; 104:888–895. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherGISTen_US
dc.subject.otherImatiniben_US
dc.subject.otherSunitiniben_US
dc.titleAdvanced or metastatic gastrointestinal stromal tumors: Systemic treatment optionsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Hematology/Oncology, Department of Internal Medicine University of Michigan, Michiganen_US
dc.contributor.affiliationotherC342 Med Inn, SPC 5848 1500 E Medical Center Dr. Ann Arbor, MI 48109‐5848. Fax: 734‐647‐7279.en_US
dc.identifier.pmid22069173en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/88051/1/21930_ftp.pdf
dc.identifier.doi10.1002/jso.21930en_US
dc.identifier.sourceJournal of Surgical Oncologyen_US
dc.identifier.citedreferenceDemetri GD, von Mehren M, Antonescu CR, et al.: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1 – S41.en_US
dc.identifier.citedreferenceNilsson B, Bumming P, Meis‐Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – A population‐based study in western Sweden. Cancer 2005; 103: 821 – 829.en_US
dc.identifier.citedreferenceBlanke CD, Demetri GD, von Mehren M, et al.: Long‐term results from a randomized phase II trial of standard‐ versus higher‐dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620 – 625.en_US
dc.identifier.citedreferenceReith JD, Goldblum JR, Lyles RH, et al.: Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577 – 585.en_US
dc.identifier.citedreferenceMiettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long‐term follow‐up. Am J Surg Pathol 2005; 29: 52 – 68.en_US
dc.identifier.citedreferenceDeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51 – 58.en_US
dc.identifier.citedreferenceHeinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342 – 4349.en_US
dc.identifier.citedreferenceHirota S, Ohashi A, Nishida T, et al.: Gain‐of‐function mutations of platelet‐derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660 – 667.en_US
dc.identifier.citedreferencePantaleo MA, Astolfi A, Di Battista M, et al.: Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target. Int J Cancer 2009; 125: 2991 – 2994.en_US
dc.identifier.citedreferenceBraconi C, Bracci R, Bearzi I, et al.: Insulin‐like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008; 19: 1293 – 1298.en_US
dc.identifier.citedreferenceAndersson J, Sihto H, Meis‐Kindblom JM, et al.: NF1‐associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005; 29: 1170 – 1176.en_US
dc.identifier.citedreferenceMiettinen M, Fetsch JF, Sobin LH, et al.: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90 – 96.en_US
dc.identifier.citedreferenceAgarwal R, Robson M: Inherited predisposition to gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009; 23: 1 – 13.en_US
dc.identifier.citedreferenceGold JS, Gonen M, Gutierrez A, et al.: Development and validation of a prognostic nomogram for recurrence‐free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 2009; 10: 1045 – 1052.en_US
dc.identifier.citedreferenceEdmonson JH, Marks RS, Buckner JC, et al.: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM‐CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20: 605 – 612.en_US
dc.identifier.citedreferenceDematteo RP, Heinrich MC, El‐Rifai WM, et al.: Clinical management of gastrointestinal stromal tumors: Before and after STI‐571. Hum Pathol 2002; 33: 466 – 477.en_US
dc.identifier.citedreferenceBerthet B, Sugarbaker TA, Chang D, et al.: Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35: 413 – 419.en_US
dc.identifier.citedreferenceEilber FC, Rosen G, Forscher C, et al.: Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6: 645 – 650.en_US
dc.identifier.citedreferenceHirota S, Isozaki K, Moriyama Y, et al.: Gain‐of‐function mutations of c‐kit in human gastrointestinal stromal tumors. Science 1998; 279: 577 – 580.en_US
dc.identifier.citedreferenceJoensuu H, Roberts PJ, Sarlomo‐Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052 – 1056.en_US
dc.identifier.citedreferenceVerweij J, Casali PG, Zalcberg J, et al.: Progression‐free survival in gastrointestinal stromal tumours with high‐dose imatinib: Randomised trial. Lancet 2004; 364: 1127 – 1134.en_US
dc.identifier.citedreferenceBlanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626 – 632.en_US
dc.identifier.citedreferenceZalcberg JR, Verweij J, Casali PG, et al.: Outcome of patients with advanced gastro‐intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751 – 1757.en_US
dc.identifier.citedreferenceEisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42 – 47.en_US
dc.identifier.citedreferenceMcAuliffe JC, Hunt KK, Lazar AJ, et al.: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16: 910 – 919.en_US
dc.identifier.citedreferenceAndtbacka RH, Ng CS, Scaife CL, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14 – 24.en_US
dc.identifier.citedreferenceHohenberger P, Oladeji O, Licht T, et al.: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST. J Clin Oncol 2009; 27: 548s (abstract 10550).en_US
dc.identifier.citedreferenceHecker A, Hecker B, Bassaly B, et al.: Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: Case report and review. World J Surg Oncol 2010; 8: 47.en_US
dc.identifier.citedreferenceSaied GM, Kensarah AM: Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg 2010; 8: 105 – 108.en_US
dc.identifier.citedreferenceDemetri GD, Wang Y, Wehrle E, et al.: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141 – 3147.en_US
dc.identifier.citedreferenceBlay JV, Le Cesne A, Ray‐Coquard I, et al.: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107 – 1113.en_US
dc.identifier.citedreferenceLe Cesne A, Ray‐Coquard I, Bui BN, et al.: Continuous versus interruption of imatinib in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 2007; 25: 546s (abstract 10005).en_US
dc.identifier.citedreferenceGuilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9: 271 – 281.en_US
dc.identifier.citedreferenceGanjoo KN, Demetri GD, Jacobs C, et al.: Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma 2009; 50: 1882 – 1884.en_US
dc.identifier.citedreferenceKerkela R, Grazette L, Yacobi R, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908 – 916.en_US
dc.identifier.citedreferenceDebiec‐Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093 – 1103.en_US
dc.identifier.citedreferenceHeinrich MC, Owzar K, Corless CL, et al.: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360 – 5367.en_US
dc.identifier.citedreferenceHeinrich MC, Maki RG, Corless CL, et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib‐resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352 – 5359.en_US
dc.identifier.citedreferenceDebiec‐Rychter M, Dumez H, Judson I, et al.: Use of c‐KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689 – 695.en_US
dc.identifier.citedreferenceCorless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357 – 5364.en_US
dc.identifier.citedreferenceMaleddu A, Pantaleo MA, Nannini M, et al.: Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 2009; 21: 1359 – 1366.en_US
dc.identifier.citedreferenceDemetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329 – 1338.en_US
dc.identifier.citedreferenceGeorge S, Blay JY, Casali PG, et al.: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45: 1959 – 1968.en_US
dc.identifier.citedreferenceZhu X, Stergiopoulos K: Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta‐analysis. Acta Oncol 2009; 48: 9 – 17.en_US
dc.identifier.citedreferenceChu TF, Rupnick MA, Kerkela R, et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011 – 2019.en_US
dc.identifier.citedreferenceDesai J, Yassa L, Marqusee E, et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660 – 664.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
21930_ftp.pdf
Size:
101.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.